Combination therapy with amantadine and interferon in naïve patients with chronic hepatitis C: Meta-analysis of individual patient data from six clinical trials

Journal of Hepatology

Volumn 40, Issue 3, 2004, Pages 478-483

  Mangia, Alessandra ^a   Leandro, Gioacchino ⁱ   Helbling, Beat ^b   Renner, Eberhard L ^b   Tabone, Marco ^c   Sidoli, Laura ^c   Caronia, Simona ^d   Foster, Graham R ^e   Zeuzem, Stephan ^f   Berg, Thomas ^g   Di Marco, Vito ^h   Cino, Nicolina ^h   Andriulli, Angelo ^a  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c MAURIZIANO HOSPITAL   (Italy)

^d ST MARY S HOSPITAL   (United Kingdom)

^e ROYAL LONDON HOSPITAL   (United Kingdom)

^f SAARLAND UNIVERSITY   (Germany)

^g CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^h UNIVERSITY OF PALERMO   (Italy)

ⁱ NATIONAL INSTITUTE FOR DIGESTIVE DISEASES   (Italy)

Author keywords

Amantadine; Chronic hepatitis C; Interferon; Meta analysis; Randomized clinical trials; Therapy

Indexed keywords

AMANTADINE; INTERFERON; RIBAVIRIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; MALE; META ANALYSIS; MONOTHERAPY; PRIORITY JOURNAL; VIREMIA;

EID: 10744224044     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2003.11.002     Document Type: Article

References (21)

1. Fried M.W., Shiffman M.L., Reddy R.K., Smith C., Marinos G., Gonçales F.L. Jr., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 347:2002;975-982.
2. Manns M.P., McHutchison J.G., Gordon S.C., Rustgi V.K., Shiffman M., Reindollar R., et al. PEG interferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet. 358:2001;958-965.
3. Mangia A., Minerva N., Annese M., Leandro G., Villani M.R., Santoro R., et al. A randomized trial of amantadine and interferon versus interferon alone as initial treatment for chronic hepatitis C. Hepatology. 33:2001;989-993.
4. Caronia S., Bassendine M.F., Barry R., Mills P., Naumov N.V., Fox R., et al. Interferon plus amantadine versus interferon alone in the treatment of naïve patients with chronic hepatitis C: a UK multicentre study. J Hepatol. 35:2001;512-516.
5. Tabone M., Lausi C., Delmastro B., Biglino A., Andreoni A., Chieppa F., et al. Interferon and amantadine in combination as initial treatment for chronic hepatitis C. J Hepatol. 35:2001;517-521.
6. Helbling B., Viani F., Gonvers J.J., Dufour J.F., Reichen J., Cathomas G., et al. Interferon and amantadine in naïve chronic hepatitis C: a double-blind, randomized, placebo-controlled trial. Hepatology. 35:2002;447-454.
7. Zeuzem S., Teuber G., Naumann U., Berg T., Raedle J., Hartmann S., Hopf U. Randomized, double-blind, placebo-controlled trial of interferon alfa2a with and without amantadine as initial treatment for chronic hepatitis C. Hepatology. 32:2000;835-841.
8. Craxì A., Lo Iacono O. Amantadine for chronic hepatitis C: a magic bullet or yet another dead duck? J Hepatol. 35:2001;527-530.
9. Di Marco V and the GRECOS study. Combination therapy with daily interferon plus amantadine versus interferon monotherapy in patients with chronic hepatitis C. Proceedings of The International Symposium on Treatment of Chronic Hepatitis C: Today's Knowledge and New Frontiers, Taormina (Italy); March 2-3, 2001.
10. EASL International Consensus Conference on Hepatitis C, Paris, 26-28 February 1999, Consensus Statement. J Hepatol. 30:1999;956-961.
11. Brown H.K., Kemptom R.A. The application of REML in clinical trials. Stat Med. 30:1994;1601-1617.
12. Brown H., Prescott R. Applied mixed models in medicine. 1999;Wiley, Chichester.
13. Lanzini A., Pigozzi M.G., Stellini R., Reggiani A., Salmi A., Andri G., et al. Interferon vs interferon+amantadine hydrochloride for treatment of chronic hepatitis C: results of a randomized controlled trial. Hepatology. 34:2001;338A.
14. Jorge F.A., Tanno H., Igartua E.B., Pinchuk L., Sorda J.A., Curciarello J., et al. Interferon induction treatment with and without amantadine HCl in patients with chronic hepatitis C. J Hepatol. 34:2001;156.
15. Engler S.H., Stremmel W., Kallinowski B.I. Interferon alpha2A induction therapy in combination with ribavirin and amantadine in naïve patients with chronic HCV infection. J Hepatol. 34:2001;177.
16. Berg T., Kronenberger B., Hinrichsen H., Gerlach T., Buggisch P., Spengler U. Triple therapy with amantadine sulphate plus ribavirin and interferon-alpha in previously untreated patients with chronic hepatitis C: results of a double blind, placebo-controlled trial. J Hepatol. 36:2002;3A.
17. Poynard T., Marcellin P., Lee S.S., Niederau C., Minuk G.S., Ideo G., et al. Randomized trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet. 352:1998;1426-1432.
18. Brillanti S., Levantesi F., Masi L., Foli M., Bolondi L. Triple antiviral therapy as a new option for patients with interferon nonresponsive chronic hepatitis C. Hepatology. 32:2000;630-634.
19. Herrine S.K., Brown R., Esposito S., Galati J.S., Bernstein D.E., Campagna J., et al. Pegasys in combination with ribavirin, mycophenolate mofetil, amantadine, or amantadine plus ribavirin in patients that relapsed on rebetron therapy: a preliminary report of a randomized, multicenter efficacy and safety study. Gastroenterology. 120:2001;384A.
20. Afdahl N., Flamm S., Imperial J.C., Malet P.F., Tong M., Campagna J., et al. Pegasys in combination therapies in patients that did not respond on rebetron therapy: a preliminary report of a randomized, multicenter efficacy and safety study. Gastroenterology. 120:2001;383A.
21. Teuber G., Berg T., Lafrenz M., Weidenbach H., Schoelmerich J., Wietzke-Braun P., et al. Randomized, controlled trial with interferon-alpha combined with ribavirin with and without amantadine sulfate in primary IFN-alpha non responsive patients with chronic hepatitis C. J Hepatol. 34:2001;23.